Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact of the partial suspension of Sciensus's manufacturing licence.

The partial suspension will remain in place until the company instigates measures to ensure the manufacturing error cannot not re-occur and we continue to monitor the company’s progress. The Medicines and Healthcare products Regulatory Agency has not been informed that the regulatory action has had any deleterious impact on patients receiving their medicines.